176 results on '"Cvetkovic, Mirjana"'
Search Results
2. Copy number variation analysis identifies MIR9-3 and MIR1299 as novel miRNA candidate genes for CAKUT
- Author
-
Zivotic, Ivan, Kolic, Ivana, Cvetkovic, Mirjana, Spasojevic-Dimitrijeva, Brankica, Zivkovic, Maja, Stankovic, Aleksandra, and Jovanovic, Ivan
- Published
- 2024
- Full Text
- View/download PDF
3. An unusual case of type I hyperlipidemia - infant with acute encephalopathy, bulging fontanel, vomiting and pink blood: a case report
- Author
-
Kalanj, Jasna, Cobeljic, Mina Goran, Jesic, Maja, Zdravkovic, Vera, Cvetkovic, Mirjana, Vukasinovic, Nadja, Andjelkovic, Marina, and Rsovac, Snezana
- Published
- 2024
- Full Text
- View/download PDF
4. Venous thromboembolism in patients with acute myeloid leukemia: development of a predictive model
- Author
-
Mitrovic, Mirjana, Pantic, Nikola, Bukumiric, Zoran, Sabljic, Nikica, Virijevic, Marijana, Pravdic, Zlatko, Cvetkovic, Mirjana, Ilic, Nikola, Rajic, Jovan, Todorovic-Balint, Milena, Vidovic, Ana, Suvajdzic-Vukovic, Nada, Thachil, Jecko, and Antic, Darko
- Published
- 2024
- Full Text
- View/download PDF
5. Clinical Guidelines for Routine Neuromonitoring in Neonatal and Pediatric Patients Supported on Extracorporeal Membrane Oxygenation
- Author
-
Pandiyan, Poornima, Cvetkovic, Mirjana, Antonini, Marta Velia, Shappley, Rebekah K. H., Karmakar, Swati A., and Raman, Lakshmi
- Published
- 2023
- Full Text
- View/download PDF
6. Risk Factors for Venous Thromboembolism in Acute Promyelocytic Leukemia.
- Author
-
Sabljic, Nikica, Pantic, Nikola, Virijevic, Marijana, Rajic, Jovan, Cvetkovic, Mirjana, Trajkovic, Lazar, Pravdic, Zlatko, Bukumiric, Zoran, Suvajdzic Vukovic, Nada, Bogdanovic, Andrija, Vidovic, Ana, Todorovic Balint, Milena, Bila, Jelena, Lekovic, Danijela, Djunic, Irena, Antic, Darko, and Mitrovic, Mirjana
- Abstract
Simple Summary: Data regarding venous thromboembolism (VTE) predictors in patients with acute promyelocytic leukemia (APL) are scarce. A retrospective study was conducted on adult patients with APL treated with all-trans retinoic acid and anthracycline. Demographic and clinical–laboratory data related to VTE were collected and analyzed, along with the predictive value of two risk assessment models (RAMs). Among the 155 patients, 28 (18.1%) had VTEs. Neither the Al-Ani RAM nor the RAM predicted VTEs in our cohort. The independent risk factors for VTE were CD114 expression (p = 0.005, OR = 6.4 IC 95%: [1.8–23.2]) and the absence of bleeding at presentation (p = 0.013, OR = 0.086 IC 95%: [0.01–0.59]). To the best of our knowledge, this is the first study showing that a higher expression of CD114 increases the risk of VTE. So far, no risk assessment model has been sufficient to stratify patients with APL according to their risk of VTE. Background: Acute promyelocytic leukemia (APL) is frequently associated with disseminated intravascular coagulation (DIC), leading to potentially life-threatening bleeding. Compared to bleeding, thromboses are a less commonly encountered problem. Objective: The objective of our study was to identify the incidence and predictive value of demographic data, clinical–laboratory parameters, and thrombosis risk assessment models (RAMs) for venous thromboembolism (VTE) in patients with APL. Methods: This study was a retrospective study conducted on adult patients with APL who were treated between 2006 and 2024 at the Clinic of Hematology UCCS with all-trans retinoic acid (ATRA) and anthracycline. The demographic and clinical–laboratory data related to VTE were collected and analyzed alongside the predictive value of two RAMs proposed by Al-Ani and Paterno and colleagues. Results: Among the one-hundred-fifty-five adult patients with APL, VTE was diagnosed in twenty-eight cases (18.1%). The most common location for thrombosis was in the central venous catheter (CVC), which affected twelve (42.8%) patients. A total of six (21.4%) patients had deep vein thrombosis (DVT), one patient (3.6%) showed a pulmonary embolism (PE), and thrombosis at unusual sites was present in nine (32.1%) patients. Our analyses showed that neither Al-Ani's RAM nor the RAM proposed by Paterno and colleagues were predictive for VTE in patients with APL. The C statistics value for the Al-Ani model was ROC = 0.514, and, for Paterno's RAM, it was ROC = 0.521. The independent risk factors for VTE, identified via multivariate analysis, were CD114 expression (p = 0.005, OR = 6.4 IC 95%: [1.8–23.2]) and the absence of bleeding at presentation (p = 0.013, OR = 0.086 IC 95%: [0.01–0.59]). Conclusions: To the best of our knowledge, this is the first study showing that a higher expression of CD114 increases the risk of VTE. The absence of bleeding at presentation in patients with APL correlates with thrombosis. Further analyses are needed to confirm these findings and help to develop therapeutic strategies to prevent VTE complications. So far, no risk assessment model has been sufficient to stratify patients with APL according to their risk of VTE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Detection of impaired renal allograft function in paediatric and young adult patients using arterial spin labelling MRI (ASL-MRI)
- Author
-
Radovic, Tijana, Jankovic, Milica M., Stevic, Ruza, Spasojevic, Brankica, Cvetkovic, Mirjana, Pavicevic, Polina, Gojkovic, Ivana, and Kostic, Mirjana
- Published
- 2022
- Full Text
- View/download PDF
8. Integration of dry-column flash chromatography with NMR and FTIR metabolomics to reveal cytotoxic metabolites from Amphoricarpos autariatus
- Author
-
Cvetković, Mirjana, Damjanović, Ana, Stanojković, Tatjana P., Đorđević, Iris, Tešević, Vele, Milosavljević, Slobodan, and Gođevac, Dejan
- Published
- 2020
- Full Text
- View/download PDF
9. Definitions of adverse events associated with extracorporeal membrane oxygenation in children: results of an international Delphi process from the ECMO-CENTRAL ARC
- Author
-
Alexander, Peta M A, Di Nardo, Matteo, Combes, Alain, Vogel, Adam M, Antonini, Marta Velia, Barrett, Nicholas, Benedetti, Giulia M, Bettencourt, Amanda, Brodie, Daniel, Gómez-Gutiérrez, René, Gorga, Stephen M, Hodgson, Carol, Kapoor, Poonam Malhotra, Le, Jennifer, MacLaren, Graeme, O’Neil, Erika R, Ostermann, Marlies, Paden, Matthew L, Patel, Neil, Rojas-Peña, Alvaro, Said, Ahmed S, Sperotto, Francesca, Willems, Ariane, Vercaemst, Leen, Yoganathan, Ajit P, Lorts, Angela, del Nido, Pedro J, Barbaro, Ryan P, Abecasis, Francisco, Al Foudri, Huda, Anders, Marc M., Angus, Derek C., Annich, Gail M., Arachchillage, Deepa J., Akcan-Arikan, Ayse, Armstrong, Aimee K., Balcells, Joan, Barrett, Meredith, Bartlett, Robert H., Belda-Hofheinz, Sylvia, Bembea, Melania M., Best, Derek J., Bonadonna, Desiree, Boonstra, Philip S., Brogan, Thomas V, Brown, Katherine L, Butragueño-Laiseca, Laura, Butt, Warwick W., Camporota, Luigi, Cardenas, Barbara, Cascarano, Maria T., Caspi, Joseph, Chen, Eric, Chiletti, Roberto, Colombo, Giovanna G., Conte, Marisa L., Crowe, Liz, Cvetkovic, Mirjana, Dalton, Heidi J., Daverio, Marco, Davidson, Mark G., Davis, Carl, DiGeronimo, Robert J., Egbunine, Ariel, Ellis, W. Cory, Fan, Eddy, Foster, Claire C, Fraser, John F., Friedman, Matthew L., Furlong-Dillard, Jamie, Fynn-Thompson, Francis, Garcia, Alejandro V., Geppert, Jeffery, Gillette, Nicole, Grazioli, Lorenzo, Greene, Christina L, Guerguerian, Anne-Marie, Guilliams, Kristin P., Haji Fortis, Jumana Y., Hao, Jianming, Heinsar, Silver, Hejduk, Mark W., Himebauch, Adam S., Horvat, Christopher M., Hoskote, Aparna, Hou, Xiaotong, Hyslop, Robert W., Ibrahim, Nicole, Ito, Takuya, Karagiannidis, Christian, Karam, Oliver, Kaushik, Shubhi, Kilbaugh, Todd J., Kim-Campbell, Nahmah, Kirsch, Roxanne E, Kormos, Robert L., Kornberger, Angela, Krucoff, Mitchell W., Lakshminrusimha, Satyan, LaRovere, Kerri L, Leger, Pierre-Louis, Levy, Philip T., Lorusso, Roberto, Lyster, Haifa, Malone, Matthew P., McMullan, D. Michael, Mečířová, Soña, Mehran, Roxana, Merz, Scott I., Mochizuki, Shuichi, Moler, Frank W., Molla, Kalkidan, Monagle, Paul, Morgan, Gareth J., Morgan, Catherine, Morice, Marie-Claude, Muszynski, Jennifer A., Najaf, Tasnim A., Nellis, Marianne E., Newburger, Jane W., O'Rourke, P. Pearl, Ostadal, Petr, Ozment, Caroline P., Pagani, Francis D., Peek, Giles J., Polito, Angelo, Priest, John R., Raman, Lakshmi, Rintoul, Natalie E., Roy, Nathalie, Rubin, Juli, Rumford, Martha, Rycus, Peter, Ryerson, Lindsay M., Sakamoto, Wakako, Segura-Matute, Susana, Shekar, Kiran, Spinella, Philip C., Spitzer, Ernest, Starr, Joanne P., Stead, Christine, Steffen, Katherine, Steiner, Marie E., Tan, Lucy, Tasker, Robert C., Taylor, J. Michael, Thiagarajan, Ravi R., Tonna, Joseph E., Ubertini, Gina M., van Leeuwen, Grace, Vang, Eric, Ventetuolo, Corey E., Venugopal, Prem S., Weinberg, Allison, Westrope, Claire, Wu, Changfu, Wylie, Gillian, Zeymer, Uwe, Zivick, Elizabeth E., and Zochios, Vasileios
- Abstract
Extracorporeal membrane oxygenation (ECMO) is a high-risk and low-volume life support with increasing clinical study. However, heterogenous outcome definitions impede data assimilation into evidence to guide practice. The Academic Research Consortium (ARC), an international collaborative forum committed to facilitating the creation of stakeholder-driven consensus nomenclature and outcomes for clinical trials of medical devices, supported the ECMO Core Elements Needed for Trials Regulation And quality of Life (ECMO-CENTRAL) ARC. The ECMO-CENTRAL ARC was assembled to develop definitions of paediatric ECMO adverse events for use in clinical trials and regulatory device evaluation. An initial candidate list of ECMO adverse events derived from the mechanical circulatory support ARC was supplemented with a review of ECMO-relevant adverse event definitions collated from literature published between Jan 1, 1988, and Feb 20, 2023. Distinct teams of international topic experts drafted separate adverse event definitions that were harmonised to existing literature when appropriate. Draft definitions were revised for paediatric ECMO relevance with input from patients, families, and an international expert panel of trialists, clinicians, statisticians, biomedical engineers, device developers, and regulatory agencies. ECMO-CENTRAL ARC was revised and disseminated across research societies and professional organisations. Up to three rounds of internet-based anonymous surveys were planned as a modified Delphi process. The expert panel defined 13 adverse event definitions: neurological, bleeding, device malfunction, acute kidney injury, haemolysis, infection, vascular access-associated injury, non-CNS thrombosis, hepatic dysfunction, right heart failure, left ventricular overload, lactic acidaemia, and hypoxaemia. Definitional structure varied. Among 165 expert panel members, 114 were eligible to vote and 111 voted. Consensus was achieved for all proposed definitions. Agreement ranged from 82% to 95%. ECMO-CENTRAL ARC paired rigorous development with methodical stakeholder involvement and dissemination to define paediatric ECMO adverse events. These definitions will facilitate new research and the assimilation of data across clinical trials and ECMO device evaluation in children.
- Published
- 2024
- Full Text
- View/download PDF
10. Deep venous thrombosis in patients with atresia of the inferior vena cava and right kidney hypoplasia (KILT syndrome): Systematic review of the literature.
- Author
-
Pantic, Nikola, Cvetkovic, Mirjana, Milin-Lazovic, Jelena, Vukmirovic, Jelica, Pavlovic, Aleksandar, Virijevic, Marijana, Pravdic, Zlatko, Kozarac, Sofija, Sabljic, Nikica, Suvajdzic-Vukovic, Nada, Dragas, Marko, and Mitrovic, Mirjana
- Subjects
- *
VENA cava inferior , *VENOUS thrombosis , *KIDNEYS , *HUMAN abnormalities , *SCIENCE databases - Abstract
Inferior vena cava (IVC) anomalies are uncommon congenital causes of deep vein thrombosis (DVT). KILT syndrome (kidney and IVC abnormalities with leg thrombosis) has only been described as case reports in the literature. Therefore, the characteristics, evaluation, and management of patients with KILT syndrome have not yet been standardized. This study aimed to systematically review and analyze the clinical and radiographic data and treatment of previously reported cases of KILT syndrome. In this systematic review, we performed a literature search of the PubMed, Scopus, and Web of Science databases in December 2023, with no restrictions on the publication date. After duplicate extractions, 4195 articles were screened. Case reports and case series reporting on KILT syndrome were included. In addition to previously published cases, we included a new case of a previously healthy 25-year-old man with KILT syndrome in the analysis. A total of 34 cases were therefore included in this study. The majority (76.5%) were male patients with a median age of 24 years. In most patients, unprovoked bilateral iliofemoral thrombosis was diagnosed, and 64.7% had left kidney abnormalities. Our study suggests that anomalies of the IVC should be suspected in all young patients, especially male patients, with proximal, recurrent, or idiopathic DVT. If an IVC anomaly is confirmed, the kidneys should be examined to monitor and preserve healthy kidneys in cases of KILT syndrome. The data collected from all patients emphasize the requirement of long-term anticoagulation and risk factor control. Surgical measures may be effective for treating symptomatic refractory cases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Biological Therapy for Inflammatory Bowel Disease During the COVID-19 Pandemic: Experiences From a Tertiary IBD Service
- Author
-
Markovic, Srdjan, Ivanovski, Tamara Knezevic, Zogovic, Branimir, Cvetkovic, Mirjana, and Svorcan, Petar
- Published
- 2020
- Full Text
- View/download PDF
12. Acute dialysis in children: results of a European survey
- Author
-
Guzzo, Isabella, de Galasso, Lara, Mir, Sevgi, Bulut, Ipek Kaplan, Jankauskiene, Augustina, Burokiene, Vilmanta, Cvetkovic, Mirjana, Kostic, Mirjana, Bayazit, Aysun Karabay, Yildizdas, Dincer, Schmitt, Claus Peter, Paglialonga, Fabio, Montini, Giovanni, Yilmaz, Ebru, Oh, Jun, Weber, Lutz, Taylan, Christina, Hayes, Wesley, Shroff, Rukshana, Vidal, Enrico, Murer, Luisa, Mencarelli, Francesca, Pasini, Andrea, Teixeira, Ana, Afonso, Alberto Caldas, Drozdz, Dorota, Schaefer, Franz, Picca, Stefano, and For the ESCAPE Network
- Published
- 2019
- Full Text
- View/download PDF
13. S308: RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN ACUTE PROMYELOCYTIC LEUKEMIA
- Author
-
Sabljic, Nikica, primary, Pantic, Nikola, additional, Bukumiric, Zoran, additional, Pravdic, Zlatko, additional, Virijevic, Marijana, additional, Suvajdzic, Nada, additional, Rajic, Jovan, additional, Vidovic, Ana, additional, Cvetkovic, Mirjana, additional, and Mitrovic, Mirjana, additional
- Published
- 2023
- Full Text
- View/download PDF
14. PB2202: NOVEL PREDICTORS FOR VENOUS AND ARTERIAL THROMBOSIS IN POLYCYTHEMIA VERA
- Author
-
Ivanović, Jelena, primary, Arsenović, Isidora, additional, Cvetkovic, Mirjana, additional, Smiljanic, Mihailo, additional, Sefer, Dijana, additional, Bogdanovic, Andrija, additional, and Lekovic, Danijela, additional
- Published
- 2023
- Full Text
- View/download PDF
15. P1655: DEEP VENOUS THROMBOSIS IN PATIENT WITH ATRESIA OF INFERIOR VENA CAVA AND RIGHT KIDNEY HYPOPLASIA (KILT SYNDROME): CASE REPORT AND SYSTEMATIC REVIEW OF THE LITERATURE
- Author
-
Pantic, Nikola, primary, Cvetkovic, Mirjana, additional, Milin-Lazovic, Jelena, additional, Virijevic, Marijana, additional, Pravdic, Zlatko, additional, Dragas, Marko, additional, Sarac, Sofija, additional, Sabljic, Nikica, additional, Suvajdzic, Nada, additional, and Mitrovic, Mirjana, additional
- Published
- 2023
- Full Text
- View/download PDF
16. P1053: NEUTROPHIL-TO-LYMPHOCYTE AND PLATELET-TO-LYMPHOCYTE RATIO AS NOVEL PROGNOSTIC BIOMARKES IN BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
- Author
-
Cvetkovic, Mirjana, primary, Ivanović, Jelena, additional, Arsenović, Isidora, additional, Smiljanic, Mihailo, additional, Karasek, Magdalena, additional, Chyrko, Olga, additional, Bogdanovic, Andrija, additional, Sobas, Marta, additional, and Lekovic, Danijela, additional
- Published
- 2023
- Full Text
- View/download PDF
17. PB2190: COMORBIDITIES PREDICT WORSE PROGNOSIS IN PATIENTS WITH POLYCYTHEMIA VERA
- Author
-
Arsenović, Isidora, primary, Ivanović, Jelena, additional, Cvetkovic, Mirjana, additional, Smiljanic, Mihailo, additional, Jakovic, Ljubomir, additional, Jovanovic, Maja Perunicic, additional, Bogdanovic, Andrija, additional, and Lekovic, Danijela, additional
- Published
- 2023
- Full Text
- View/download PDF
18. The Role of Ultrasonography in the Diagnosis of Functional Dyspepsia.
- Author
-
Cvetkovic, Mirjana, Jovanovic, Igor, Crevar-Marinovic, Slobodanka, Brankovic, Marija, Mandic, Olga, Maksimovic, Jasmina, Zdravkovic, Nataša, Simovic, Stefan, and Stanisavljevic, Natasa
- Subjects
- *
INDIGESTION , *ULTRASONIC imaging , *GASTRIC emptying , *ABDOMINAL pain , *CONTROL groups - Abstract
Functional dyspepsia (FD) is a syndrome mostly diagnosed by subjective patients' symptoms after excluding organic, systemic and metabolic diseases. Aim: The goal of this study is to evaluate gastric emptying in patients with functional dyspepsia, by measuring the antral area (cm2) after the intake of a test meal using ultrasonography as an objective and widely applicable method. Material and Methods: This study included 30 patients (mean age of 46.53 ±9.73 years) with symptoms of FD according to the ROMA IV criteria and 30 healthy individuals (mean age of 42.87 ±4.42 years). A 5 MHz ultrasound probe was used to measure the stomach antral area at 6 different time points: in the fasting state, following the meal intake at 5, 30, 60, 90 and 120 min postprandially. Results: The antral area was statistically significantly larger after a 30-minute postprandial period in patients with FD comparing to healthy controls (p<0.05). There was a statistically significant difference in the rate of gastric emptying at 120 minutes in patients with functional dyspepsia, compared to healthy subjects (p <0.01). Patients with postprandial distress syndrome had the average value of gastric emptying 48.25 compared to 56.09 in patients with epigastric pain syndrome (p <0.05). The slowest emptying was observed in patients with nausea and postprandial fullness (p <0.05). Conclusion: Functional dyspepsia is associated with delayed gastric emptying. Using ultrasonography to measure the antral area helps us to assess gastric emptying and therefore to assess patients with functional dyspepsia. The antral area was significantly larger in patients with functional dyspepsia compared to healthy subjects after the test meal, suggesting slower gastric emptying in the dyspeptic patients. Since the diagnosis of functional dyspepsia is based mostly on diverse patients' symptoms, using ultrasonography to measure the antral area helps us to objectively assess this problem. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Incidence, risk factors, and outcome of asymptomatic central nervous system involvement in adult patients with acute myeloid leukemia.
- Author
-
Virijevic, Marijana, Kraguljac‐Kurtovic, Nada, Mitrovic, Mirjana, Jakovic, Ljubomir, Bukumuric, Zoran, Pantic, Nikola, Sabljic, Nikica, Pravdic, Zlatko, Cvetkovic, Mirjana, Knezevic, Vesna, Dragovic‐Ivancevic, Tijana, Djunić, Irena, Rajic, Jovan, Milosevic, Violeta, Todorovic‐Balint, Milena, Vidovic, Ana, and Suvajdzic‐Vukovic, Nada
- Subjects
ACUTE myeloid leukemia ,CENTRAL nervous system ,LEUKOCYTE count ,ASYMPTOMATIC patients ,CENTRAL nervous system injuries ,SYMPTOMS - Abstract
Examination of central nervous system (CNS) involvement is not routine diagnostic practice in adult patients with acute myeloid leukemia (AML). Therefore, many asymptomatic patients with CNS involvement might go undetected. The effect of CNS involvement on the AML disease course is not well defined, with conflicting results regarding clinical outcome. This study aimed to determine the incidence of asymptomatic CNS involvement in AML estimated by multiparametric flow cytometry of cerebrospinal fluid (MFC‐CSF) at diagnosis, the related potential risk factors, and prognosis. In total, 645 patients with de novo AML were screened; 183 (28.4%) of them fulfilled institutional practice for MFC‐CSF analysis based on presence of CNS symptoms and/or clinical features. CNS symptoms and signs were observed in 8/183 (4.4%) patients, but most patients (175/183, 95.6%) were asymptomatic. In the asymptomatic group, 73/175 (41.7%) patients had positive or suspicious cerebrospinal fluid (CSF) findings categorized as CNS positive (CNSpos) and 102/175 (58.3%) had normal CNS findings categorized as CNS negative (CNSneg). The presence of leukemic blasts was confirmed in 81/183 (44.3%) patients; the total incidence of CNS involvement in the whole AML group was 12.6% (81/645). Compared with asymptomatic patients with CNSneg, those with CNSpos had a significantly higher frequency of lymphadenopathy, white blood cell count ≥30 × 109/L, presence of the monocytic phenotype, and a high percentage of bone marrow (BM) blasts. The multivariate logistic regression model identified monocytic phenotype (p = 0.047) and high percentage of BM blasts (p = 0.042) as predictors for CNSpos. CNSpos did not affect overall survival in patients with AML. There was a higher incidence of CNS involvement in asymptomatic adult patients with de novo AML, emphasizing possible undervalued rates of CNS disease at diagnosis. Prospective studies should determine whether diagnostic lumbar puncture for MFC‐CSF analysis and CNS prophylaxis could contribute to better selection and prognosis in this patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Headspace Analysis of Volatile Compounds From Fruits of Selected Vegetable Species of Apiaceae Family
- Author
-
Acimovic, Milica G., primary, Cvetkovic, Mirjana T., additional, Stankovic, Jovana M., additional, Tesevic, Vele V., additional, and Todosijevic, Marina M., additional
- Published
- 2018
- Full Text
- View/download PDF
21. Downregulation of fibrosis related hsa-miR-29c-3p in human CAKUT.
- Author
-
Macak, Natasa, Jovanovic, Ivan, Zivkovic, Maja, Mitrovic, Kristina, Cvetkovic, Mirjana, Kostic, Mirjana, and Stankovic, Aleksandra
- Subjects
URETERIC obstruction ,GENE expression ,RENAL fibrosis ,FIBROSIS ,GENETIC regulation - Abstract
Congenital anomalies of the kidney and urinary tract (CAKUT) represent structural and functional urinary system malformations and take place as one of the most common congenital malformations with an incidence of 1:500. Ureteral obstruction-induced hydronephrosis is associated with renal fibrosis and chronic kidney diseases in the pediatric CAKUT. We aimed to construct interaction network of previously bioinformatically associated miRNAs with CAKUT differentially expressed genes in order to prioritize those associated with fibrotic process and to experimentally validate the expression of selected miRNAs in CAKUT patients compared to control group. We constructed interaction network of hsa-miR-101-3p, hsa-miR-101-5p and hsa-miR-29c-3p that showed significant association with fibrosis. The top enriched molecular pathway was extracellular matrix-receptor interaction (adjusted p =.0000263). We experimentally confirmed expression of three miRNAs (hsa-miR-29c-3p, hsa-miR-101-3p and hsa-miR-101-5p) in obstructed ureters (ureteropelvic junction obstruction and primary obstructive megaureter) and vesicoureteral reflux. The hsa-miR-29c-3p was shown to have lower expression in both patient groups compared to controls. Relative levels of hsa-miR-101-5p and hsa-miR-101-3p showed significant positive correlations in both groups of patients. Statistically significant correlation was observed between hsa-miR-101 (-3p and -5p) and hsa-miR-29c-3p only in the obstructed group. The significant downregulation of anti-fibrotic hsa-miR-29c-3p in obstructive CAKUT could explain activation of genes involved in fibrotic processes. As miRNAs are promising candidates in therapeutic approaches our results need further measurement of fibrotic markers or assessment of extent of fibrosis and functional evaluation of hsa-miR-29c. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. “Bridging the Gap” international ECLS training and simulation - evaluation of the 10th educational corner on EuroELSO congress 2022 in London, United Kingdom
- Author
-
Cvetkovic, Mirjana, primary, Antonini, Marta V, additional, Rosenberg, Alex, additional, Meadows, Christopher IS, additional, Dąbrowski, Marek, additional, Puslecki, Mateusz, additional, Fawzy Hassan, Ibrahim, additional, Fowles, Jo-Anne, additional, O’Callaghan, Maura, additional, Stefaniak, Sebastian, additional, Riera, Jordi, additional, Barrett, Nicholas A, additional, Bělohlávek, Jan, additional, Di Nardo, Matteo, additional, Hoskote, Aparna, additional, and Swol, Justyna, additional
- Published
- 2023
- Full Text
- View/download PDF
23. Long-Term Quality of Life in Congenital Heart Disease Surgical Survivors: Multicenter Retrospective Study of Surgical and ICU Explanatory Factors
- Author
-
Marino, Bradley S., primary, Cassedy, Amy, additional, Brown, Katherine L., additional, Franklin, Rodney, additional, Gaynor, J. William, additional, Cvetkovic, Mirjana, additional, Laker, Simon, additional, Levinson, Katherine, additional, MacGloin, Helen, additional, Mahony, Lynn, additional, McQuillan, Annette, additional, Mussatto, Kathleen, additional, O’Shea, Deirdre, additional, Newburger, Jane, additional, Sykes, Michelle, additional, Teele, Sarah A., additional, Wernovsky, Gil, additional, and Wray, Jo, additional
- Published
- 2023
- Full Text
- View/download PDF
24. 72 An educational initiative with the London academy of excellence tottenham (LAET) to provide 6th form students with an insight into nursing and medicine. An initiative by the GLA education team using videoconferencing
- Author
-
Broadhurst, Joanne, primary, Simpson, Gabrielle, additional, and Cvetkovic, Mirjana, additional
- Published
- 2023
- Full Text
- View/download PDF
25. Supplemental Material - 'Bridging the Gap' international ECLS training and simulation - evaluation of the 10th educational corner on EuroELSO congress 2022 in London, United Kingdom
- Author
-
Cvetkovic, Mirjana, Antonini, Marta V, Rosenberg, Alex, Meadows, Christopher IS, Dąbrowski, Marek, Puslecki, Mateusz, Fawzy Hassan, Ibrahim, Fowles, Jo-Anne, O’Callaghan, Maura, Stefaniak, Sebastian, Riera, Jordi, Barrett, Nicholas A, Bělohlávek, Jan, Di Nardo, Matteo, Hoskote, Aparna, and Swol, Justyna
- Subjects
FOS: Clinical medicine ,Cardiology ,110323 Surgery - Abstract
Supplemental Material for “Bridging the Gap” international ECLS training and simulation - evaluation of the 10th educational corner on EuroELSO congress 2022 in London, United Kingdom by Mirjana Cvetkovic, Marta V Antonini, Alex Rosenberg, Christopher IS Meadows, Marek Dąbrowski, Mateusz Puslecki, Ibrahim Fawzy Hassan, Jo-Anne Fowles, Maura O’Callaghan, Sebastian Stefaniak, Jordi Riera, Nicholas A Barrett, Jan Bělohlávek, Matteo Di Nardo, Aparna Hoskote and Justyna Swol in Perfusion
- Published
- 2023
- Full Text
- View/download PDF
26. Factors Predicting Malignant Occurrence and Polyp Recurrence after the Endoscopic Resection of Large Colorectal Polyps: A Single Center Experience
- Author
-
Mandic, Olga, primary, Jovanovic, Igor, additional, Cvetkovic, Mirjana, additional, Maksimovic, Jasmina, additional, Radonjic, Tijana, additional, Popovic, Maja, additional, Nikolic, Novica, additional, and Brankovic, Marija, additional
- Published
- 2022
- Full Text
- View/download PDF
27. Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors.
- Author
-
Mitrovic, Mirjana, Pantic, Nikola, Sabljic, Nikica, Bukumiric, Zoran, Virijevic, Marijana, Pravdic, Zlatko, Cvetkovic, Mirjana, Rajic, Jovan, Bodrozic, Jelena, Milosevic, Violeta, Todorovic-Balint, Milena, Vidovic, Ana, Suvajdzic-Vukovic, Nada, and Antic, Darko
- Subjects
THROMBOSIS risk factors ,THROMBOSIS ,CARDIOVASCULAR diseases risk factors ,ACADEMIC medical centers ,ARTERIES ,ACQUISITION of data ,RETROSPECTIVE studies ,RISK assessment ,CANCER patients ,MEDICAL records ,GENETIC markers ,BODY mass index ,LONGITUDINAL method ,COMORBIDITY - Abstract
Simple Summary: Patients with hematological malignancies have an increased risk of arterial thrombosis (ATE). Data about incidence and risk factors for ATE development in patients with acute myeloid leukemia (AML) are missing. Out of 626 AML patients, 18 (2.9%) patients developed ATE in the median time of 3 months. Our study showed that the risk of ATE was increased in AML patients with cardiovascular comorbidities, previous thrombosis, adverse cytogenetic risk as well as BMI > 30. Background: Patients with hematological malignancies have an increased risk of arterial thrombotic events (ATEs) after diagnosis, compared to matched controls without cancer. However, data about incidence and risk factors for ATE development in patients with acute myeloid leukemia (AML) are missing. Aim: The objectives of this study were to determine the incidence of ATE in non-promyelocytic-AML patients and to define the potential risk factors for ATE development. Methods: We conducted a retrospective cohort study of adult patients with newly diagnosed AML. The primary outcome was the occurrence of confirmed ATE, defined as myocardial infarction, stroke or critical limb ischemia. Results: Out of 626 eligible AML patients, 18 (2.9%) patients developed ATE in the median time of 3 (range: 0.23–6) months. Half of these patients died due to ATE complications. Five parameters were predictors of ATE: BMI > 30 (p = 0.000, odds ratio [OR] 20.488, 95% CI: 6.581–63.780), prior history of TE (p = 0.041, OR 4.233, 95% CI: 1.329–13.486), presence of comorbidities (p = 0.027, OR 5.318, 95% CI: 1.212–23.342), presence of cardiovascular comorbidities (p < 0.0001, OR 8.0168, 95% CI: 2.948–21.800) and cytogenetic risk score (p = 0.002, OR 2.113, 95% CI: 1.092–5.007). Conclusions: Our study showed that patients with AML are at increased risk of ATE. The risk was increased in patients with cardiovascular comorbidities, previous thrombosis, adverse cytogenetic risk as well as BMI > 30. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. MMP-1 and -3 haplotype is associated with congenital anomalies of the kidney and urinary tract
- Author
-
Djuric, Tamara, Zivkovic, Maja, Milosevic, Biljana, Andjelevski, Magdalena, Cvetkovic, Mirjana, Kostic, Mirjana, and Stankovic, Aleksandra
- Subjects
Birth defects -- Genetic aspects -- Care and treatment -- Research ,Chronic kidney failure -- Genetic aspects -- Drug therapy -- Research ,Genetic polymorphisms -- Physiological aspects -- Research ,Health - Abstract
Background Congenital anomalies of the kidney and urinary tract (CAKUT) are a common cause of progressive chronic kidney disease that may lead to end-stage renal disease and renal replacement therapy in childhood. Altered expression or activity of matrix metalloproteinases (MMPs) have been found in CAKUT. The MMP-1, -3, and -8 polymorphisms studied here are located in the gene promoters and alter expression. Our aim was to investigate associations of MMP polymorphisms, solely and in haplotypes, with CAKUT in children. Methods A case-control study with 101 pediatric patients and 281 controls was performed. The MMP-1 (-1607 1G/2G), -3 (5A/6A), and -8 (-799 C/T) genotypes were determined by PCR-restriction fragment length polymorphism. Results We found statistically significant associations of MMP-3 5A/6A polymorphism (p Conclusions MMP-3 genotypes and MMP-3 and -1 haplotypes encompassing either MMP-8-799C or T alleles were associated with CAKUT and obstructive uropathies in pediatric patients Still, functional and association studies are needed to elucidate evident roles of MMPs in CAKUT Keywords CAKUT * Obstructive uropathy * Matrix metalloproteinase * Gene * Polymorphisms, Introduction Congenital anomalies of the kidney and urinary tract (CAKUT) include a variety of anatomical and histological malformations during faulty embryonic development, implying both obstructive and functional abnormalities All together, [...]
- Published
- 2014
- Full Text
- View/download PDF
29. International survey of neuromonitoring and neurodevelopmental outcome in children and adults supported on extracorporeal membrane oxygenation in Europe.
- Author
-
Cvetkovic, Mirjana, Chiarini, Giovanni, Belliato, Mirko, Delnoij, Thijs, Zanatta, Paolo, Taccone, Fabio Silvio, Miranda, Dinis dos Reis, Davidson, Mark, Matta, Nashwa, Davis, Carl, IJsselstijn, Hanneke, Schmidt, Matthieu, Broman, Lars Mikael, Donker, Dirk W, Vlasselaers, Dirk, David, Piero, Di Nardo, Matteo, Muellenbach, Ralf M, Mueller, Thomas, and Barrett, Nicholas A
- Subjects
- *
BIOMARKERS , *INTERNATIONAL relations , *ELECTROENCEPHALOGRAPHY , *EXTRACORPOREAL membrane oxygenation , *TRANSCRANIAL Doppler ultrasonography , *NEURAL development , *PATIENT monitoring , *PEARSON correlation (Statistics) , *QUESTIONNAIRES , *DESCRIPTIVE statistics , *BRAIN injuries , *DATA analysis software , *LONGITUDINAL method , *NEURORADIOLOGY - Abstract
Background: Adverse neurological events during extracorporeal membrane oxygenation (ECMO) are common and may be associated with devastating consequences. Close monitoring, early identification and prompt intervention can mitigate early and late neurological morbidity. Neuromonitoring and neurocognitive/neurodevelopmental follow-up are critically important to optimize outcomes in both adults and children. Objective: To assess current practice of neuromonitoring during ECMO and neurocognitive/neurodevelopmental follow-up after ECMO across Europe and to inform the development of neuromonitoring and follow-up guidelines. Methods: The EuroELSO Neurological Monitoring and Outcome Working Group conducted an electronic, web-based, multi-institutional, multinational survey in Europe. Results: Of the 211 European ECMO centres (including non-ELSO centres) identified and approached in 23 countries, 133 (63%) responded. Of these, 43% reported routine neuromonitoring during ECMO for all patients, 35% indicated selective use, and 22% practiced bedside clinical examination alone. The reported neuromonitoring modalities were NIRS (n = 88, 66.2%), electroencephalography (n = 52, 39.1%), transcranial Doppler (n = 38, 28.5%) and brain injury biomarkers (n = 33, 24.8%). Paediatric centres (67%) reported using cranial ultrasound, though the frequency of monitoring varied widely. Before hospital discharge following ECMO, 50 (37.6%) reported routine neurological assessment and 22 (16.5%) routinely performed neuroimaging with more paediatric centres offering neurological assessment (65%) as compared to adult centres (20%). Only 15 (11.2%) had a structured longitudinal follow-up pathway (defined followup at regular intervals), while 99 (74.4%) had no follow-up programme. The majority (n = 96, 72.2%) agreed that there should be a longitudinal structured follow-up for ECMO survivors. Conclusions: This survey demonstrated significant variability in the use of different neuromonitoring modalities during and after ECMO. The perceived importance of neuromonitoring and follow-up was noted to be very high with agreement for a longitudinal structured follow-up programme, particularly in paediatric patients. Scientific society endorsed guidelines and minimum standards should be developed to inform local protocols. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Primary immune thrombocytopenia in adults - disease considerations
- Author
-
Suvajdzic-Vukovic, Nada, primary, Pantic, Nikola, additional, Pravdic, Zlatko, additional, Cvetkovic, Mirjana, additional, Sabljic, Nikica, additional, and Mitrovic, Mirjana, additional
- Published
- 2022
- Full Text
- View/download PDF
31. Terpene relationships among some soft and hard pine species
- Author
-
Krstic, Gordana, primary, Nikolic, Biljana, additional, Todosijevic, Marina, additional, Mitic, Zorica, additional, Stankovic-Jeremic, Jovana, additional, Cvetkovic, Mirjana, additional, Bojovic, Srdjan, additional, and Marin, Petar, additional
- Published
- 2022
- Full Text
- View/download PDF
32. Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension in a 5-year-old Girl with No Risk Factors - A Case Report
- Author
-
Sharma, Sudivya, primary, Rahman, Adeel, additional, Beeman, Arun, additional, Moledina, Shahin, additional, Robertson, Alex, additional, Jenkins, David, additional, Cvetkovic, Mirjana, additional, and Muthialu, Nagarajan, additional
- Published
- 2022
- Full Text
- View/download PDF
33. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
- Author
-
Adamina, Michel, Bonovas, Stefanos, Raine, Tim, Spinelli, Antonino, Warusavitarne, Janindra, Armuzzi, Alessandro, Bachmann, Oliver, Bager, Palle, Biancone, Livia, Bokemeyer, Bernd, Bossuyt, Peter, Burisch, Johan, Collins, Paul, Doherty, Glen, El-Hussuna, Alaa, Ellul, Pierre, Fiorino, Gionata, Frei-Lanter, Cornelia, Furfaro, Federica, Gingert, Christian, Gionchetti, Paolo, Gisbert, Javier P, Gomollon, Fernando, Lorenzo, Marien Gonzalez, Gordon, Hannah, Hlavaty, Tibor, Juillerat, Pascal, Katsanos, Konstantinos, Kopylov, Uri, Krustins, Eduards, Kucharzik, Torsten, Lytras, Theodore, Maaser, Christian, Magro, Fernando, Marshall, John Kenneth, Myrelid, Par, Pellino, Gianluca, Rosa, Isadora, Sabino, Joao, Savarino, Edoardo, Stassen, Laurents, Torres, Joana, Uzzan, Mathieu, Vavricka, Stephan, Verstockt, Bram, Zmora, Oded, Akyuz, Filiz, Atreya, Raja, De Acosta, Manuel Barreiro, Bettenworth, Dominik, Bjorkesten, Clas-Goran, Bogut, Ante, Calabrese, Emma, Cvetkovic, Mirjana, Dewint, Pieter, Djuranovic, Srdjan, Drobne, David, Duricova, Dana, Filippi, Jerome, Hogenauer, Christoph, Kaimakliotis, Ioannis, Kiudelis, Gediminas, Klopocka, Maria, Koutroubakis, Ioannis, Krznaric, Zeljko, Laja, Hendrik, Moschen, Alexander, Novak, Gregor, Potapov, Alexander, Tuire, Ilus, Turcan, Svetlana, van Dop, Willemijn, van Schaik, Fiona, Vieira, Ana Isabel, Viennot, Stephanie, Wildt, Signe, Adamina, Michel, Bonovas, Stefano, Raine, Tim, Spinelli, Antonino, Warusavitarne, Janindra, Armuzzi, Alessandro, Bachmann, Oliver, Bager, Palle, Biancone, Livia, Bokemeyer, Bernd, Bossuyt, Peter, Burisch, Johan, Collins, Paul, Doherty, Glen, El-Hussuna, Alaa, Ellul, Pierre, Fiorino, Gionata, Frei-Lanter, Cornelia, Furfaro, Federica, Gingert, Christian, Gionchetti, Paolo, Gisbert, Javier P, Gomollon, Fernando, Lorenzo, Marien González, Gordon, Hannah, Hlavaty, Tibor, Juillerat, Pascal, Katsanos, Konstantino, Kopylov, Uri, Krustins, Eduard, Kucharzik, Torsten, Lytras, Theodore, Maaser, Christian, Magro, Fernando, Marshall, John Kenneth, Myrelid, Pär, Pellino, Gianluca, Rosa, Isadora, Sabino, Joao, Savarino, Edoardo, Stassen, Laurent, Torres, Joana, Uzzan, Mathieu, Vavricka, Stephan, Verstockt, Bram, Zmora, Oded, Surgery, MUMC+: MA Heelkunde (9), MUMC+: MA AIOS Heelkunde (9), RS: NUTRIM - R2 - Liver and digestive health, Adamina M., Bonovas S., Raine T., Spinelli A., Warusavitarne J., Armuzzi A., Bachmann O., Bager P., Biancone L., Bokemeyer B., Bossuyt P., Burisch J., Collins P., Doherty G., El-Hussuna A., Ellul P., Fiorino G., Frei-Lanter C., Furfaro F., Gingert C., Gionchetti P., Gisbert J.P., Gomollon F., Gonzalez Lorenzo M., Gordon H., Hlavaty T., Juillerat P., Katsanos K., Kopylov U., Krustins E., Kucharzik T., Lytras T., Maaser C., Magro F., Marshall J.K., Myrelid P., Pellino G., Rosa I., Sabino J., Savarino E., Stassen L., Torres J., Uzzan M., Vavricka S., Verstockt B., and Zmora O.
- Subjects
Crohn’s disease ,intersphincteric fistula tract ,pouch-anal anastomosis ,inflammatory bowel disease [IBD] ,FECAL DIVERSION ,Disease ,Inflammatory bowel disease ,surgery ,vedolizumab-treated patients ,Crohn Disease ,Maintenance therapy ,Induction therapy ,Intestine, Small ,EVIDENCE-BASED CONSENSUS ,Medicine ,POSTOPERATIVE COMPLICATIONS ,Certolizumab pegol ,610 Medicine & health ,Surgical treatment ,POUCH-ANAL ANASTOMOSIS ,TO-END ANASTOMOSIS ,Crohn's disease ,Gastroenterology ,ANTI-TNF THERAPY ,General Medicine ,Inflammatory bowel disease (IBD) ,Life Sciences & Biomedicine ,medicine.drug ,medicine.medical_specialty ,Abdominal Abscess ,MEDLINE ,postoperative complications ,Humans ,Rectal Fistula ,INTRAABDOMINAL SEPTIC COMPLICATIONS ,Intensive care medicine ,VEDOLIZUMAB-TREATED PATIENTS ,Science & Technology ,evidence-based consensus ,Gastroenterology & Hepatology ,inflammatory-bowel-disease ,intraabdominal septic complications ,business.industry ,medicine.disease ,INTERSPHINCTERIC FISTULA TRACT ,business ,Intestinal Obstruction ,INFLAMMATORY-BOWEL-DISEASE - Abstract
This article is the second in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn's disease. The first article covers medical management; the present article addresses surgical management, including preoperative aspects and drug management before surgery. It also provides technical advice for a variety of common clinical situations. Both articles together represent the evidence-based recommendations of the ECCO for Crohn's disease and an update of previous guidelines. ispartof: JOURNAL OF CROHNS & COLITIS vol:14 issue:2 pages:155-168 ispartof: location:England status: published
- Published
- 2019
- Full Text
- View/download PDF
34. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
- Author
-
David T Rubin, Iris Dotan, Aaron DuVall, Yoram Bouhnik, Graham Radford-Smith, Peter D R Higgins, Daniel S Mishkin, Pablo Arrisi, Astrid Scalori, Young S Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, Julian Panés, Abdulkhakov Rustem, Abu Bakar Norasiah, Aguilar Humberto, Aizenberg Diego, Akpinar Hale, Akriviadis Evangelos, Alexeeva Olga, Alikhanov Bagdadi, Alvarisqueta Andres, Ananthakrishnan Ashwin, Andrews Jane, Arlukowicz Tomasz, Atkinson Nathan, Atug Ozlen, Bafutto Mauro, Balaz Jozef, Bamias George, Banic Marko, Baranovsky Andrey, Barbalaco Neto Guerino, Basaranoglu Metin, Baum Curtis, Baydanov Stefan, Bennetts William, Besisik Fatih, Bhaskar Sudhir, Bielasik Andrzej, Bilianskyi Leonid, Bilir Bahri, Blaha Pavol, Bohman Verle, Borissova Julia, Borzan Vladimir, Bosques-Padilla Francisco, Bouhnik Yoram, Brooker James, Budko Tetiana, Budzak Igor, Bunganic Ivan, Chapman Jonathon, Che' Aun Azlida, Chernykh Tatiana, Chiorean Michael, Chopey Ivan, Christodoulou Dimitrios, Chu Pui Shan, Chumakova Galina, Cummins Andrew, Cunliffe Robert, Cvetkovic Mirjana, Dagli Ulku, Danilkiewicz Wit Cezary, Datsenko Olena, de Magalhães Francesconi Carlos Fernando, Debinski Henry, Deminova Elena, Derova Jelena, Ding John Nik, Dmitrieva Julia, Dolgikh Oleg, Douda Tomas, Drobinski Piotr, Dryden Gerald, Duarte Gaburri Pedro, DuVall George Aaron, Dvorkin Mikhail, Ennis Craig, Erzin Yusuf, Fadieienko Galyna, Fediv Oleksandr, Fedorishina Olga, Fedurco Miroslav, Fejes Roland, Fernandez Jorge, Fernandez Monica Lorena, Flores Lucky, Freilich Bradley, Friedenberg Keith, Fuster Sergio, Gawdis-Wojnarska Beata, Gil Parada Fabio Leonel, Gimenez Edgardo Daniel, Golovchenko Nataliia, Golovchenko Oleksandr, Gonciarz Maciej, Gonen Can, Gordon Glenn, Gregus Milos, Grinevich Vladimir, Guajardo Rodriguez Rogelio, Hall Stephen, Hanson John, Hartleb Marek, Hebuterne Xavier, Hendy Peter, Herring Robert, Hetzel David, Higgins Peter, Hilal Raouf, Hilmi Ida Normiha, Hlavaty Tibor, Holman Richard, Holtmann Gerald, Hong John, Horvath Frantisek, Hospodarskyy Ihor, Hrstic Irena, Hulagu Sadettin, Ibarra Verdugo Luis Alberto, Ibegbu Ikechukwu, Inns Stephen, Ivashkin Vladimir, Izanec James, Jain Rajesh, Jamrozik-Kruk Zofia, Kamburov Victor, Karagiannis John, Karakan Tarkan, Karczewski Marek, Kasherininova Irina, Katz Seymour, Kaufman Barry, Kazenaite Edita, Kholina Irina, Khurana Sunil, Kierkus Jaroslaw, Kiselevska Anzela, Kleczkowski Dariusz, Klymenko Volodymyr, Knezevic Slavko, Kondusz-Szklarz Malgorzata, Korablina Natalya, Korczowski Bartosz, Kosturkov Lyubomir, Kotzev Iskren, Kouklakis Georgios, Koutroubakis Ioannis, Krause Richard, Kronborg Ian, Krstic Miodrag, Krznaric Zeljko, Krzyzanowski Mikolaj, Kulig Grazyna, Kull Karin, Kupcinskas Limas, Lamet Mark, Latinovic Radakovic Tatjana, Leong Rupert, Leung Wai Keung, Levine Henry, Li Michael Kin Kong, Libanez Bessa Campelo Braga Lúcia, Livzan Maria, Lohdanidi Tetiana, Louzada Pereira Maria Helena, Lowe John, Luetic Kresimir, Lukas Milan, Lymar Yurii, Macrae Finlay, Mäelt Anu, Maev Igor, Mamos Arkadiusz, Mantzaris Gerasimos, Margus Benno, Marinova Ivanka, Markevych Inna, Markov Mario, Markovic Srdjan, Marquez Velasquez Juan Ricardo, Mazzoleni Felipe, Mimidis Konstantinos, Mitchell Brent, Moore Gregory, Morales Garza Luis Alonso, Moscatello Salvatore, Mostovoy Yuriy, Mountifield Reme, Nagorni Aleksandar, Neshta Viacheslav, Obrezan Andrey, Oliinyk Oleksandr, Oliveira Santana Silva Genoile, Orzeszko Maria, Pavlenko Vladimir, Pavlov Dimitar, Penkova Mariana, Peric Sasa, Petkov Plamen, Petrov Asen, Petrov Plamen, Petrova Michaela, Phillips Raymond, Pintor Chacon Sergio, Polianskyi Igor, Prystupa Ludmyla, Pugach Mykhailo, Pugas Carvalho Ana Teresa, Pukitis Aldis, Pumprla Jiri, Pyrogovskyy Volodymyr, Racz Istvan, Radford-Smith Graham, Raja Ali Raja Affendi, Ramos Castañeda Daniel, Ramos Júnior Odery, Rausher David, Rebrov Andrey, Regula Jaroslaw, Rezk Amir, Reznikova Viktoriia, Rishko Iaroslava, Roblin Xavier, Rodoman Grigory, Rojas Rodriguez Carlos Arturo, Rozciecha Jerzy, Rubin David, Rupinski Maciej, Rzucidlo Jacek, Sablin Oleg, Sahin Halil, Salleh Rosemi, Samuel Douglas, Scafuto Scotton Antonio, Schnabel Robert, Schulman Michael, Schultz Michael, Scott John, Sedghi Shahriar, Shaban Ahmad, Shapina Marina, Shaposhnikova Natalia, Shchukina Oksana, Sherman Alex, Shumikhina Irina, Simanenkov Vladimir, Simonov Vladislav, Simulionis Giedrius, Skrypnyk Igor, Sliwowski Zbigniew, Smid Jan, Solaiman Mahmood, Soofi Najm, Soufleris Konstantinos, Spassova Zoia, Stanislavchuk Mykola, Stec-Michalska Krystyna, Stifft Jonathas, Stoinov Simeon, Stoyanova Girgina, Sultan Keith, Surace Lindsey, Takov Dimitar, Tälli Jaak, Tankova Ludmila, Tanno Hugo, Tarabar Dino, Tarakji Elias, Tchernev Konstantin, Tee Hoi Poh, Thin Lena, Thomas Carlton, Tishaeva Irina, Todorova Tsveta, Tokarenko Oleksandr, Tolmanis Ivars, Tomasevic Ratko, Trofimov Vasiliy, Tulassay Zsolt, Unsal Belkis, Uzunova-Genova Alma, Valentine John, Valuyskikh Ekaterina, Vasconcellos Eduardo, Vasileva Galina, Vasylyuk Sergiy, Vaughn Byron, Velazquez Francisco, Vizir Vadym, Vladimirov Borislav, Volfova Miroslava, Vyhnalek Petr, Wallace Ian, Waluga Marek, Watkins William, Weber John, Wiechowska-Kozlowska Anna, Winstead Nathaniel, Wojtkiewicz Pawel, Wozniak-Stolarska Barbara, Yacyshyn Bruce, Yakovlev Alexey, Younes Ziad, Yukie Sassaki Lígia, Yuksel Ilhami, Zachar Jan, Zaltman Cyrla, Zdravkovic Petrovic Natasa, Zhdan Vyacheslav, Zinchenko Maryna, and Zymla Maciej
- Subjects
Ulcerative Colitis Flare ,Adult ,Male ,medicine.medical_specialty ,Adolescent ,Population ,Placebo ,Antibodies, Monoclonal, Humanized ,Gastroenterology ,Severity of Illness Index ,Placebos ,Young Adult ,Double-Blind Method ,Gastrointestinal Agents ,Internal medicine ,Adalimumab ,Medicine ,Humans ,Adverse effect ,education ,Aged ,education.field_of_study ,Hepatology ,business.industry ,Remission Induction ,Colonoscopy ,Induction Chemotherapy ,Middle Aged ,medicine.disease ,Symptom Flare Up ,Ulcerative colitis ,Concomitant ,Etrolizumab ,Colitis, Ulcerative ,Female ,business ,medicine.drug - Abstract
Summary Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission relative to placebo in patients with moderately to severely active ulcerative colitis. The HIBISCUS studies aimed to compare the efficacy and safety of etrolizumab to adalimumab and placebo for induction of remission in patients with moderately to severely active ulcerative colitis. Methods HIBISCUS I and HIBISCUS II were identically designed, multicentre, phase 3, randomised, double-blind, placebo-controlled and active-controlled studies of etrolizumab, adalimumab, and placebo in adult (18–80 years) patients with moderately to severely active ulcerative colitis (Mayo Clinic total score [MCS] of 6–12 with an endoscopic subscore of ≥2, a rectal bleeding subscore of ≥1, and a stool frequency subscore of ≥1) who were naive to tumour necrosis factor inhibitors. All patients had an established diagnosis of ulcerative colitis for at least 3 months, corroborated by both clinical and endoscopic evidence, and evidence of disease extending at least 20 cm from the anal verge. In both studies, patients were randomly assigned (2:2:1) to receive subcutaneous etrolizumab 105 mg once every 4 weeks; subcutaneous adalimumab 160 mg on day 1, 80 mg at week 2, and 40 mg at weeks 4, 6, and 8; or placebo. Randomisation was stratified by baseline concomitant treatment with corticosteroids, concomitant treatment with immunosuppressants, and baseline disease activity. All patients and study site personnel were masked to treatment assignment. The primary endpoint was induction of remission at week 10 (defined as MCS of 2 or lower, with individual subscores of 1 or lower, and rectal bleeding subscore of 0) with etrolizumab compared with placebo. Pooled analyses of both studies comparing etrolizumab and adalimumab were examined for several clinical and endoscopic endpoints. Efficacy was analysed using a modified intent-to-treat population, defined as all randomly assigned patients who received at least one dose of study drug. These trials are registered with ClinicalTrials.gov , NCT02163759 (HIBISCUS I), NCT02171429 (HIBISCUS II). Findings Between Nov 4, 2014, and May 25, 2020, each study screened 652 patients (HIBISCUS I) and 613 patients (HIBISCUS II). Each study enrolled and randomly assigned 358 patients (HIBISCUS I etrolizumab n=144, adalimumab n=142, placebo n=72; HIBISCUS II etrolizumab n=143; adalimumab n=143; placebo n=72). In HIBISCUS I, 28 (19·4%) of 144 patients in the etrolizumab group and five (6·9%) of 72 patients in the placebo group were in remission at week 10, with an adjusted treatment difference of 12·3% (95% CI 1·6 to 20·6; p=0·017) in favour of etrolizumab. In HIBISCUS II, 26 (18·2%) of 143 patients in the etrolizumab group and eight (11·1%) of 72 patients in the placebo group were in remission at week 10, with an adjusted treatment difference of 7·2% (95% CI –3·8 to 16·1; p=0·17). In the pooled analysis, etrolizumab was not superior to adalimumab for induction of remission, endoscopic improvement, clinical response, histological remission, or endoscopic remission; however, similar numerical results were observed in both groups. In HIBISCUS I, 50 (35%) of 144 patients in the etrolizumab group reported any adverse event, compared with 61 (43%) of 142 in the adalimumab group and 26 (36%) of 72 in the placebo group. In HIBISCUS II, 63 (44%) of 143 patients in the etrolizumab group reported any adverse event, as did 62 (43%) of 143 in the adalimumab group and 33 (46%) in the placebo group. The most common adverse event in all groups was ulcerative colitis flare. The incidence of serious adverse events in the pooled patient population was similar for etrolizumab (15 [5%] of 287) and placebo (seven [5%] of 144) and lower for adalimumab (six [2%] of 285). Two patients in the etrolizumab group died; neither death was deemed to be treatment related. Interpretation Etrolizumab was superior to placebo for induction of remission in HIBISCUS I, but not in HIBISCUS II. Etrolizumab was well tolerated in both studies. Funding F Hoffmann-La Roche.
- Published
- 2021
35. International survey of neuromonitoring and neurodevelopmental outcome in children and adults supported on extracorporeal membrane oxygenation in Europe
- Author
-
Cvetkovic, Mirjana, primary, Chiarini, Giovanni, additional, Belliato, Mirko, additional, Delnoij, Thijs, additional, Zanatta, Paolo, additional, Taccone, Fabio Silvio, additional, Miranda, Dinis dos Reis, additional, Davidson, Mark, additional, Matta, Nashwa, additional, Davis, Carl, additional, IJsselstijn, Hanneke, additional, Schmidt, Matthieu, additional, Broman, Lars Mikael, additional, Donker, Dirk W, additional, Vlasselaers, Dirk, additional, David, Piero, additional, Di Nardo, Matteo, additional, Muellenbach, Ralf M, additional, Mueller, Thomas, additional, Barrett, Nicholas A, additional, Lorusso, Roberto, additional, Belohlavek, Jan, additional, and Hoskote, Aparna, additional
- Published
- 2021
- Full Text
- View/download PDF
36. sj-pdf-2-prf-10.1177_02676591211042563 – Supplemental material for International survey of neuromonitoring and neurodevelopmental outcome in children and adults supported on extracorporeal membrane oxygenation in Europe
- Author
-
Cvetkovic, Mirjana, Chiarini, Giovanni, Belliato, Mirko, Delnoij, Thijs, Zanatta, Paolo, Taccone, Fabio Silvio, Miranda, Dinis dos Reis, Davidson, Mark, Matta, Nashwa, Davis, Carl, IJsselstijn, Hanneke, Schmidt, Matthieu, Broman, Lars Mikael, Donker, Dirk W, Vlasselaers, Dirk, David, Piero, Di Nardo, Matteo, Muellenbach, Ralf M, Mueller, Thomas, Barrett, Nicholas A, Lorusso, Roberto, Belohlavek, Jan, and Hoskote, Aparna
- Subjects
FOS: Clinical medicine ,Cardiology ,110323 Surgery - Abstract
Supplemental material, sj-pdf-2-prf-10.1177_02676591211042563 for International survey of neuromonitoring and neurodevelopmental outcome in children and adults supported on extracorporeal membrane oxygenation in Europe by Mirjana Cvetkovic, Giovanni Chiarini, Mirko Belliato, Thijs Delnoij, Paolo Zanatta, Fabio Silvio Taccone, Dinis dos Reis Miranda, Mark Davidson, Nashwa Matta, Carl Davis, Hanneke IJsselstijn, Matthieu Schmidt, Lars Mikael Broman, Dirk W Donker, Dirk Vlasselaers, Piero David, Matteo Di Nardo, Ralf M Muellenbach, Thomas Mueller, Nicholas A Barrett, Roberto Lorusso, Jan Belohlavek and Aparna Hoskote in Perfusion
- Published
- 2021
- Full Text
- View/download PDF
37. sj-pdf-1-prf-10.1177_02676591211042563 – Supplemental material for International survey of neuromonitoring and neurodevelopmental outcome in children and adults supported on extracorporeal membrane oxygenation in Europe
- Author
-
Cvetkovic, Mirjana, Chiarini, Giovanni, Belliato, Mirko, Delnoij, Thijs, Zanatta, Paolo, Taccone, Fabio Silvio, Miranda, Dinis dos Reis, Davidson, Mark, Matta, Nashwa, Davis, Carl, IJsselstijn, Hanneke, Schmidt, Matthieu, Broman, Lars Mikael, Donker, Dirk W, Vlasselaers, Dirk, David, Piero, Di Nardo, Matteo, Muellenbach, Ralf M, Mueller, Thomas, Barrett, Nicholas A, Lorusso, Roberto, Belohlavek, Jan, and Hoskote, Aparna
- Subjects
FOS: Clinical medicine ,Cardiology ,110323 Surgery - Abstract
Supplemental material, sj-pdf-1-prf-10.1177_02676591211042563 for International survey of neuromonitoring and neurodevelopmental outcome in children and adults supported on extracorporeal membrane oxygenation in Europe by Mirjana Cvetkovic, Giovanni Chiarini, Mirko Belliato, Thijs Delnoij, Paolo Zanatta, Fabio Silvio Taccone, Dinis dos Reis Miranda, Mark Davidson, Nashwa Matta, Carl Davis, Hanneke IJsselstijn, Matthieu Schmidt, Lars Mikael Broman, Dirk W Donker, Dirk Vlasselaers, Piero David, Matteo Di Nardo, Ralf M Muellenbach, Thomas Mueller, Nicholas A Barrett, Roberto Lorusso, Jan Belohlavek and Aparna Hoskote in Perfusion
- Published
- 2021
- Full Text
- View/download PDF
38. The quantitative structure-retention relationship of the GC-MS profile of yarrow essential oil
- Author
-
Acimovic, Milica, primary, Pezo, Lato, additional, Stankovic-Jeremic, Jovana, additional, Todosijevic, Marina, additional, Rat, Milica, additional, Tesevic, Vele, additional, and Cvetkovic, Mirjana, additional
- Published
- 2021
- Full Text
- View/download PDF
39. Achillea clypeolata Sibth. & Sm. essential oil composition and QSRR model for predicting retention indices
- Author
-
Acimovic, Milica, primary, Pezo, Lato, additional, Cvetkovic, Mirjana, additional, Stankovic, Jovana, additional, and Cabarkapa, Ivana, additional
- Published
- 2021
- Full Text
- View/download PDF
40. Phytochemical study of the genus Amphoricarpos
- Author
-
Djordjevic, Iris, primary, Cvetkovic, Mirjana, additional, Jadranin, Milka, additional, Bojovic, Srdjan, additional, Andjelkovic, Boban, additional, Sofrenic, Ivana, additional, and Simic, Katarina, additional
- Published
- 2021
- Full Text
- View/download PDF
41. Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein
- Author
-
Kirn, Richard B., Wandel, Christoph, Leake, Brenda, Cvetkovic, Mirjana, Fromm, Martin F., Dempsey, Peter J., Roden, Mark M., Belas, Frank, Chaudhary, Ajai K., Roden, Dan M., Wood, Alastair J. J., and Wilkinson, Grant R.
- Published
- 1999
- Full Text
- View/download PDF
42. QSRR Model for Predicting Retention Indices of Geraniol Chemotype of Thymus serpyllum Essential Oil
- Author
-
Acimovic, Milica, primary, Pezo, Lato, additional, Jeremic, Jovana Stankovic, additional, Cvetkovic, Mirjana, additional, Rat, Milica, additional, Cabarkapa, Ivana, additional, and Tesevic, Vele, additional
- Published
- 2020
- Full Text
- View/download PDF
43. NMR-based metabolomics study of Amphoricarpos species from Montenegro
- Author
-
Cvetković, Mirjana, Anđelković, Boban, Stevanović, Vladimir, Jadranin, Milka, Đorđević, Iris, Tešević, Vele, Milosavljević, Slobodan, and Gođevac, Dejan
- Published
- 2018
- Full Text
- View/download PDF
44. Effect of Weather Conditions, Location and Fertilization on Coriander Fruit Essential Oil Quality
- Author
-
Cvetkovic Mirjana, Stankovic Jovana, and Acimovic Milica
- Subjects
fertilizers ,Sabinene ,Geranyl acetate ,01 natural sciences ,Biochemistry ,Analytical Chemistry ,law.invention ,chemistry.chemical_compound ,Camphor ,Linalool ,law ,Coriandrum sativum ,Essential oil ,GC-MS analysis ,2. Zero hunger ,Limonene ,locations ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,weather conditions ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Horticulture ,Agronomy ,13. Climate action ,Myrcene ,Camphene - Abstract
Coriander was grown for seed in the field experiment conducted on three localities during two years by applying six different fertilization regimes. There were 11 compounds identified in the coriander essential oil by GC-MS. The main component was linalool with 73.23%, followed by α-pinene (8.43%), γterpinene (7.64%), camphor (3.07%), limonene (1.78%) and geranyl acetate (1.57%), while other compounds (camphene, p-cymene, β-pinene, myrcene and sabinene) were present in less than 1%. The content of all compounds was strongly influenced by weather conditions during the year, while the application of different fertilizers significantly influenced the content of linalool, α-pinene, γ-terpinene and limonene. However, the influence of location was not statistically significant. It can be concluded that growing coriander in dry climate is more favorable for linalool accumulation in essential oil than moderate to humid climate. Also, fertilization positively influences linalool content in coriander essent...
- Published
- 2016
- Full Text
- View/download PDF
45. Association between timing of dialysis initiation and clinical outcomes in the paediatric population: an ESPN/ERA-EDTA registry study
- Author
-
Preka, Evgenia, primary, Bonthuis, Marjolein, additional, Harambat, Jerome, additional, Jager, Kitty J, additional, Groothoff, Jaap W, additional, Baiko, Sergey, additional, Bayazit, Aysun K, additional, Boehm, Michael, additional, Cvetkovic, Mirjana, additional, Edvardsson, Vidar O, additional, Fomina, Svitlana, additional, Heaf, James G, additional, Holtta, Tuula, additional, Kis, Eva, additional, Kolvek, Gabriel, additional, Koster-Kamphuis, Linda, additional, Molchanova, Elena A, additional, Muňoz, Marina, additional, Neto, Gisela, additional, Novljan, Gregor, additional, Printza, Nikoleta, additional, Sahpazova, Emilija, additional, Sartz, Lisa, additional, Sinha, Manish D, additional, Vidal, Enrico, additional, Vondrak, Karel, additional, Vrillon, Isabelle, additional, Weber, Lutz T, additional, Weitz, Marcus, additional, Zagozdzon, Ilona, additional, Stefanidis, Constantinos J, additional, and Bakkaloglu, Sevcan A, additional
- Published
- 2019
- Full Text
- View/download PDF
46. Association between timing of dialysis initiation and clinical outcomes in the paediatric population: an ESPN/ERA-EDTA registry study
- Author
-
Preka, Evgenia, Bonthuis, Marjolein, Harambat, Jerome, Jager, Kitty J., Groothoff, Jaap W., Baiko, Sergey, Bayazit, Aysun K., Boehm, Michael, Cvetkovic, Mirjana, Edvardsson, Vidar O., Fomina, Svitlana, Heaf, James G., Holtta, Tuula, Kis, Eva, Kolvek, Gabriel, Koster-Kamphuis, Linda, Molchanova, Elena A., Munoz, Marina, Neto, Gisela, Novljan, Gregor, Printza, Nikoleta, Sahpazova, Emilija, Sartz, Lisa, Sinha, Manish D., Vidal, Enrico, Vondrak, Karel, Vrillon, Isabelle, Weber, Lutz T., Weitz, Marcus, Zagozdzon, Ilona, Stefanidis, Constantinos J., Bakkaloglu, Sevcan A., Preka, Evgenia, Bonthuis, Marjolein, Harambat, Jerome, Jager, Kitty J., Groothoff, Jaap W., Baiko, Sergey, Bayazit, Aysun K., Boehm, Michael, Cvetkovic, Mirjana, Edvardsson, Vidar O., Fomina, Svitlana, Heaf, James G., Holtta, Tuula, Kis, Eva, Kolvek, Gabriel, Koster-Kamphuis, Linda, Molchanova, Elena A., Munoz, Marina, Neto, Gisela, Novljan, Gregor, Printza, Nikoleta, Sahpazova, Emilija, Sartz, Lisa, Sinha, Manish D., Vidal, Enrico, Vondrak, Karel, Vrillon, Isabelle, Weber, Lutz T., Weitz, Marcus, Zagozdzon, Ilona, Stefanidis, Constantinos J., and Bakkaloglu, Sevcan A.
- Abstract
Background There is no consensus regarding the timing of dialysis therapy initiation for end-stage kidney disease (ESKD) in children. As studies investigating the association between timing of dialysis initiation and clinical outcomes are lacking, we aimed to study this relationship in a cohort of European children who started maintenance dialysis treatment. Methods We used data on 2963 children from 21 different countries included in the European Society of Pediatric Nephrology/European Renal Association-European Dialysis and Transplant Association Registry who started renal replacement therapy before 18years of age between 2000 and 2014. We compared two groups according to the estimated glomerular filtration rate (eGFR) at start: eGFR >= 8mL/min/1.73 m(2) (early starters) and eGFR >= 8mL/min/1.73 m(2) (late starters). The primary outcomes were patient survival and access to transplantation. Secondary outcomes were growth and cardiovascular risk factors. Sensitivity analyses were performed to account for selection- and lead time-bias. Results The median eGFR at the start of dialysis was 6.1 for late versus 10.5mL/min/1.73 m(2) for early starters. Early starters were older [median: 11.0, interquartile range (IQR): 5.7-14.5 versus 9.4, IQR: 2.6-14.1years]. There were no differences observed between the two groups in mortality and access to transplantation at 1, 2 and 5 years of follow-up. One-year evolution of height standard deviation scores was similar among the groups, whereas hypertension was more prevalent among late initiators. Sensitivity analyses resulted in similar findings. Conclusions We found no evidence for a clinically relevant benefit of early start of dialysis in children with ESKD. Presence of cardiovascular risk factors, such as high blood pressure, should be taken into account when deciding to initiate or postpone dialysis in children with ESKD, as this affects the survival.
- Published
- 2019
47. Association between timing of dialysis initiation and clinical outcomes in the paediatric population:an ESPN/ERA-EDTA registry study
- Author
-
Preka, Evgenia, Bonthuis, Marjolein, Harambat, Jerome, Jager, Kitty J, Groothoff, Jaap W, Baiko, Sergey, Bayazit, Aysun K, Boehm, Michael, Cvetkovic, Mirjana, Edvardsson, Vidar O, Fomina, Svitlana, Heaf, James G, Holtta, Tuula, Kis, Eva, Kolvek, Gabriel, Koster-Kamphuis, Linda, Molchanova, Elena A, Muňoz, Marina, Neto, Gisela, Novljan, Gregor, Printza, Nikoleta, Sahpazova, Emilija, Sartz, Lisa, Sinha, Manish D, Vidal, Enrico, Vondrak, Karel, Vrillon, Isabelle, Weber, Lutz T, Weitz, Marcus, Zagozdzon, Ilona, Stefanidis, Constantinos J, Bakkaloglu, Sevcan A, Preka, Evgenia, Bonthuis, Marjolein, Harambat, Jerome, Jager, Kitty J, Groothoff, Jaap W, Baiko, Sergey, Bayazit, Aysun K, Boehm, Michael, Cvetkovic, Mirjana, Edvardsson, Vidar O, Fomina, Svitlana, Heaf, James G, Holtta, Tuula, Kis, Eva, Kolvek, Gabriel, Koster-Kamphuis, Linda, Molchanova, Elena A, Muňoz, Marina, Neto, Gisela, Novljan, Gregor, Printza, Nikoleta, Sahpazova, Emilija, Sartz, Lisa, Sinha, Manish D, Vidal, Enrico, Vondrak, Karel, Vrillon, Isabelle, Weber, Lutz T, Weitz, Marcus, Zagozdzon, Ilona, Stefanidis, Constantinos J, and Bakkaloglu, Sevcan A
- Published
- 2019
48. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
- Author
-
Rubin, David T, Dotan, Iris, DuVall, Aaron, Bouhnik, Yoram, Radford-Smith, Graham, Higgins, Peter D R, Mishkin, Daniel S, Arrisi, Pablo, Scalori, Astrid, Oh, Young S, Tole, Swati, Chai, Akiko, Chamberlain-James, Kirsten, Lacey, Stuart, McBride, Jacqueline, Panés, Julian, Abdulkhakov, Rustem, Abu Bakar, Norasiah, Aguilar, Humberto, Aizenberg, Diego, Akpinar, Hale, Akriviadis, Evangelos, Alexeeva, Olga, Alikhanov, Bagdadi, Alvarisqueta, Andres, Ananthakrishnan, Ashwin, Andrews, Jane, Arlukowicz, Tomasz, Atkinson, Nathan, Atug, Ozlen, Bafutto, Mauro, Balaz, Jozef, Bamias, George, Banic, Marko, Baranovsky, Andrey, Barbalaco Neto, Guerino, Basaranoglu, Metin, Baum, Curtis, Baydanov, Stefan, Bennetts, William, Besisik, Fatih, Bhaskar, Sudhir, Bielasik, Andrzej, Bilianskyi, Leonid, Bilir, Bahri, Blaha, Pavol, Bohman, Verle, Borissova, Julia, Borzan, Vladimir, Bosques-Padilla, Francisco, Bouhnik, Yoram, Brooker, James, Budko, Tetiana, Budzak, Igor, Bunganic, Ivan, Chapman, Jonathon, Che' Aun, Azlida, Chernykh, Tatiana, Chiorean, Michael, Chopey, Ivan, Christodoulou, Dimitrios, Chu, Pui Shan, Chumakova, Galina, Cummins, Andrew, Cunliffe, Robert, Cvetkovic, Mirjana, Dagli, Ulku, Danilkiewicz, Wit Cezary, Datsenko, Olena, de Magalhães Francesconi, Carlos Fernando, Debinski, Henry, Deminova, Elena, Derova, Jelena, Ding, John Nik, Dmitrieva, Julia, Dolgikh, Oleg, Douda, Tomas, Drobinski, Piotr, Dryden, Gerald, Duarte Gaburri, Pedro, DuVall, George Aaron, Dvorkin, Mikhail, Ennis, Craig, Erzin, Yusuf, Fadieienko, Galyna, Fediv, Oleksandr, Fedorishina, Olga, Fedurco, Miroslav, Fejes, Roland, Fernandez, Jorge, Fernandez, Monica Lorena, Flores, Lucky, Freilich, Bradley, Friedenberg, Keith, Fuster, Sergio, Gawdis-Wojnarska, Beata, Gil Parada, Fabio Leonel, Gimenez, Edgardo Daniel, Golovchenko, Nataliia, Golovchenko, Oleksandr, Gonciarz, Maciej, Gordon, Glenn, Gregus, Milos, Grinevich, Vladimir, Guajardo Rodriguez, Rogelio, Hall, Stephen, Hanson, John, Hartleb, Marek, Hebuterne, Xavier, Hendy, Peter, Herring, Robert, Higgins, Peter, Hilal, Raouf, Hilmi, Ida Normiha, Hlavaty, Tibor, Holman, Richard, Holtmann, Gerald, Hong, John, Horvath, Frantisek, Hospodarskyy, Ihor, Hrstic, Irena, Hulagu, Sadettin, Ibarra Verdugo, Luis Alberto, Ibegbu, Ikechukwu, Inns, Stephen, Ivashkin, Vladimir, Izanec, James, Jain, Rajesh, Jamrozik-Kruk, Zofia, Kamburov, Victor, Karagiannis, John, Karakan, Tarkan, Karczewski, Marek, Kasherininova, Irina, Katz, Seymour, Kaufman, Barry, Kazenaite, Edita, Kholina, Irina, Khurana, Sunil, Kiselevska, Anzela, Kleczkowski, Dariusz, Klymenko, Volodymyr, Knezevic, Slavko, Kondusz-Szklarz, Malgorzata, Korablina, Natalya, Korczowski, Bartosz, Kosturkov, Lyubomir, Kotzev, Iskren, Kouklakis, Georgios, Koutroubakis, Ioannis, Krause, Richard, Kronborg, Ian, Krstic, Miodrag, Krznaric, Zeljko, Krzyzanowski, Mikolaj, Kulig, Grazyna, Kull, Karin, Kupcinskas, Limas, Lamet, Mark, Latinovic Radakovic, Tatjana, Leong, Rupert, Leung, Wai Keung, Levine, Henry, Li, Michael Kin Kong, Libanez Bessa Campelo Braga, Lúcia, Livzan, Maria, Lohdanidi, Tetiana, Louzada Pereira, Maria Helena, Lowe, John, Luetic, Kresimir, Lukas, Milan, Lymar, Yurii, Macrae, Finlay, Mäelt, Anu, Maev, Igor, Mamos, Arkadiusz, Mantzaris, Gerasimos, Margus, Benno, Marinova, Ivanka, Markevych, Inna, Markov, Mario, Markovic, Srdjan, Marquez Velasquez, Juan Ricardo, Mazzoleni, Felipe, Mimidis, Konstantinos, Mitchell, Brent, Moore, Gregory, Morales Garza, Luis Alonso, Moscatello, Salvatore, Mostovoy, Yuriy, Mountifield, Reme, Nagorni, Aleksandar, Neshta, Viacheslav, Obrezan, Andrey, Oliinyk, Oleksandr, Oliveira Santana Silva, Genoile, Orzeszko, Maria, Pavlenko, Vladimir, Pavlov, Dimitar, Penkova, Mariana, Peric, Sasa, Petkov, Plamen, Petrov, Asen, Petrov, Plamen, Petrova, Michaela, Phillips, Raymond, Pintor Chacon, Sergio, Polianskyi, Igor, Prystupa, Ludmyla, Pugach, Mykhailo, Pukitis, Aldis, Pumprla, Jiri, Pyrogovskyy, Volodymyr, Racz, Istvan, Radford-Smith, Graham, Raja Ali, Raja Affendi, Ramos Castañeda, Daniel, Ramos Júnior, Odery, Rausher, David, Rebrov, Andrey, Regula, Jaroslaw, Rezk, Amir, Reznikova, Viktoriia, Rishko, Iaroslava, Roblin, Xavier, Rodoman, Grigory, Rojas Rodriguez, Carlos Arturo, Rozciecha, Jerzy, Rubin, David, Rupinski, Maciej, Rzucidlo, Jacek, Sablin, Oleg, Sahin, Halil, Samuel, Douglas, Scafuto Scotton, Antonio, Schnabel, Robert, Schulman, Michael, Schultz, Michael, Scott, John, Sedghi, Shahriar, Shaban, Ahmad, Shapina, Marina, Shaposhnikova, Natalia, Shchukina, Oksana, Sherman, Alex, Shumikhina, Irina, Simanenkov, Vladimir, Simonov, Vladislav, Simulionis, Giedrius, Skrypnyk, Igor, Sliwowski, Zbigniew, Smid, Jan, Solaiman, Mahmood, Soofi, Najm, Soufleris, Konstantinos, Spassova, Zoia, Stanislavchuk, Mykola, Stec-Michalska, Krystyna, Stifft, Jonathas, Stoinov, Simeon, Stoyanova, Girgina, Sultan, Keith, Surace, Lindsey, Takov, Dimitar, Tälli, Jaak, Tankova, Ludmila, Tanno, Hugo, Tarabar, Dino, Tarakji, Elias, Tchernev, Konstantin, Thin, Lena, Thomas, Carlton, Tishaeva, Irina, Todorova, Tsveta, Tokarenko, Oleksandr, Tolmanis, Ivars, Tomasevic, Ratko, Trofimov, Vasiliy, Tulassay, Zsolt, Unsal, Belkis, Uzunova-Genova, Alma, Valentine, John, Valuyskikh, Ekaterina, Vasconcellos, Eduardo, Vasileva, Galina, Vasylyuk, Sergiy, Vaughn, Byron, Velazquez, Francisco, Vizir, Vadym, Vladimirov, Borislav, Volfova, Miroslava, Vyhnalek, Petr, Wallace, Ian, Waluga, Marek, Watkins, William, Weber, John, Wiechowska-Kozlowska, Anna, Winstead, Nathaniel, Wojtkiewicz, Pawel, Wozniak-Stolarska, Barbara, Yacyshyn, Bruce, Yakovlev, Alexey, Younes, Ziad, Yukie Sassaki, Lígia, Yuksel, Ilhami, Zachar, Jan, Zaltman, Cyrla, Zdravkovic Petrovic, Natasa, Zhdan, Vyacheslav, Zinchenko, Maryna, and Zymla, Maciej
- Abstract
Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission relative to placebo in patients with moderately to severely active ulcerative colitis. The HIBISCUS studies aimed to compare the efficacy and safety of etrolizumab to adalimumab and placebo for induction of remission in patients with moderately to severely active ulcerative colitis.
- Published
- 2022
- Full Text
- View/download PDF
49. Cuticular chemoprofile of the fruit fly drosophila subobscura (diptera, drosophilidae)
- Author
-
Paykovic-Lucic, S., Todosijevic, Marina M., Savic, Tatjana T., Trajkovic, Jelena D., Cvetkovic, Mirjana T., Stankovic, Jovana M., Dragana Miličić, Lucic, Luka R., Tornic, Vladimir T., Makarov, Slobodan E., and Vujisic, Ljubodrag V.
- Subjects
Drosophila subobscura ,cuticular hydrocarbons ,sexual dimorphism ,fungi - Abstract
In insects, cuticular hydrocarbon (CHC) profile is involved in many important biological functions and may vary in different conditions. Among fruit fly species, Drosophila subobscura is one of the most frequently used in genetic, ecological and evolutionary research, because of its rich chromosomal polymorphism, specific behavioral repertoires and habitat preferences. In this work, we identified and quantified cuticular chemoprofile of D. subobscura. Using gas chromatography (GC) and gas chromatography coupled with mass spectrometry (GC-MS), 25 chemical compounds were found in males and 23 compounds were found in females. Further, ANOVA confirmed significant sexual dimorphism in cuticular chemoprofile amounts. Knowledge of cuticular chemistry could contribute to further research in D. subobscura, starting from behavioral, up to ecological, since this species is recognized as an important model system for the study and monitoring of global climate changes. © 2018, Pakistan Agricultural Scientists Forum. All rights reserved.
- Published
- 2018
50. Leaf epicuticular waxes of eleven Euphorbia species (Euphorbiaceae) from the Central Balkans: Impact on chemotaxonomy
- Author
-
Krstic, Gordana, primary, Aljancic, Ivana, additional, Stankovic, Jovana, additional, Cvetkovic, Mirjana, additional, Marin, Petar, additional, Janackovic, Pedja, additional, and Tesevic, Vele, additional
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.